CompletedNCT01886469
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
Medication studyAges 6–17Canada
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Saskatoon, CanadaSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJuly 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Canada
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01886469
- Official title
Show the full official title
A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.
Recruitment & locations
CompletedSaskatoon
Questions about this study
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Did this study involve medication?
Yes. The study involved medication, including HLD100-B, HLD100-C and HLD100-E.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A Fixed-Dose, Study of LY2216684 in Pediatric people with Attention Deficit/Hyperactivity Disorder